Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea

September 22, 2026 7:00 AM

Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a royalty and milestone interest in Ryjunea, a pediatric myopia treatment marketed by Santen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found